PE20081612A1 - Analogos de las pterinas - Google Patents
Analogos de las pterinasInfo
- Publication number
- PE20081612A1 PE20081612A1 PE2008000117A PE2008000117A PE20081612A1 PE 20081612 A1 PE20081612 A1 PE 20081612A1 PE 2008000117 A PE2008000117 A PE 2008000117A PE 2008000117 A PE2008000117 A PE 2008000117A PE 20081612 A1 PE20081612 A1 PE 20081612A1
- Authority
- PE
- Peru
- Prior art keywords
- amino
- oxo
- compounds
- pteridin
- dihydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A COMPUESTOS ANALOGOS DE LA TETRABIOPTERINA DE FORMULA (I) DONDE R3, R4, R5, R6 Y R7 SON CADA UNO H; R1 Y R2 JUNTOS SON -C(Rc)Rd- Y FORMAN UN ANILLO DE CINCO MIEMBROS O SON H, CICLOALQUILO(C3-C8), ALQUILO(C3-C40), AMINOGLUCOSILO, ALQUENILENHETEROARILO C(O)(C2-C40), ENTRE OTROS, EN DONDE Rc Y Rd JUNTOS SON OXO O CADA UNO SON H, CICLOALQUILO(C3-C8), ALQUENILO(C2-C40), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: DIDODECANOATO DE BH4, CLORHIDRATO DE 2-AMINO-5-(2-AMINO-3-METIL-PENTANOIL)-6-(1,2-DIHIDROXI-PROPIL)-5,6,7,8-TETRAHIDRO-1H-PTERIDIN-4-ONA, TRIFLUOROACETATO DEL ACIDO 2-{2-AMINO-5-[2-AMINO-6-(1,2-DIHIDROXI-PROPIL)-4-OXO-4,6,7,8-TETRAHIDRO-1H-PTERIDIN-5-IL]-5-OXO-PENTANOILAMINO}-PROPIONICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN METODO DE DETECCION DE BIOPTERINA EN UNA MEZCLA DE ESPECIES DE BIOPTERINA MEDIANTE HPLC. DICHOS COMPUESTOS SON UTILES COMO PROFARMACOS DE LA TETRAHIDROBIOPTERINA SIENDO UTILES EN EL TRATAMIENTO DE HIPERTENSION, ATEROSCLEROSIS, HIPERFENILALANEMIA, RESISTENCIA A LA INSULINA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88472707P | 2007-01-12 | 2007-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20081612A1 true PE20081612A1 (es) | 2008-11-12 |
Family
ID=39535519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008000117A PE20081612A1 (es) | 2007-01-12 | 2008-01-11 | Analogos de las pterinas |
Country Status (10)
Country | Link |
---|---|
US (2) | US20100016328A1 (es) |
EP (1) | EP2114944A2 (es) |
JP (1) | JP2010515747A (es) |
AR (1) | AR064874A1 (es) |
AU (1) | AU2008206486C1 (es) |
CA (1) | CA2675134A1 (es) |
CL (1) | CL2008000094A1 (es) |
PE (1) | PE20081612A1 (es) |
TW (1) | TW200843778A (es) |
WO (1) | WO2008089008A2 (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101969953B (zh) | 2008-01-03 | 2013-01-09 | 生物马林药物股份有限公司 | 用于治疗bh4反应性疾病的喋呤类似物 |
CN101959891A (zh) | 2008-01-07 | 2011-01-26 | 生物马林药物股份有限公司 | 合成四氢生物蝶呤的方法 |
WO2011132435A1 (ja) * | 2010-04-22 | 2011-10-27 | 学校法人日本大学 | 脳機能障害予防・改善用の薬剤及び飲食物 |
CA2827679C (en) | 2011-02-18 | 2020-06-02 | Alexion Pharma International Sarl | Methods for synthesizing molybdopterin precursor z derivatives |
EP2751071B1 (en) * | 2011-08-31 | 2019-11-27 | Jill C. Milne | Fatty acid amides, compositions and methods of use |
WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
CN104622856A (zh) * | 2011-10-31 | 2015-05-20 | 约翰霍普金斯大学 | 用于治疗自闭症的方法和组合物 |
CA2872975A1 (en) | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for the treatment of neurological disorders |
AU2013257742A1 (en) | 2012-05-07 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
SG11201407318UA (en) | 2012-05-10 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of metabolic syndrome |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
JP2015518855A (ja) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 粘膜炎の治療のための組成物および方法 |
CA2873096A1 (en) | 2012-05-23 | 2013-11-28 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
SG11201407322QA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of multiple sclerosis |
US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
SG11201407325YA (en) | 2012-09-08 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammation and lipid disorders |
WO2014041446A2 (en) * | 2012-09-17 | 2014-03-20 | Mahesh Kandula | Compositions and methods for the treatment of metabolic diseases |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
CA2914461A1 (en) | 2013-06-04 | 2014-12-11 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
WO2016110865A1 (en) | 2015-01-06 | 2016-07-14 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
WO2016046835A1 (en) | 2014-09-26 | 2016-03-31 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
CN107207403A (zh) | 2014-09-29 | 2017-09-26 | 塞尔利克斯生物私人有限公司 | 用于治疗多发性硬化的组合物和方法 |
SG11201703369WA (en) | 2014-10-27 | 2017-05-30 | Cellix Bio Private Ltd | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
WO2017171894A1 (en) * | 2016-04-01 | 2017-10-05 | University Of Utah Research Foundation | Methods of treating peripheral vascular diseases, including systemic sclerosis vasculopathy |
GB2566516A (en) | 2017-09-15 | 2019-03-20 | Univ Oxford Innovation Ltd | Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria |
WO2019175328A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4pathwayactivationandusethereoffortreatingcancer |
WO2019175332A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity |
US11471963B2 (en) | 2019-01-25 | 2022-10-18 | Black & Decker Inc. | Reciprocating saw blade |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2601215A (en) * | 1948-03-17 | 1952-06-17 | American Cyanamid Co | Process of preparing dihydropterins |
US3505329A (en) * | 1968-02-06 | 1970-04-07 | Smithkline Corp | Process for the synthesis of biopterin |
JPS574990A (en) * | 1980-05-09 | 1982-01-11 | Bisukonchiini Matsukusu | Polyacylated tetrahydropterin derivative and manufacture |
JPS5883691A (ja) * | 1981-11-13 | 1983-05-19 | Kanegafuchi Chem Ind Co Ltd | 1′,2′−ジアシル−(6r,s)−5,6,7,8−テトラヒドロ−l−ビオプテリンおよびその製法 |
CH651755A5 (en) * | 1982-03-03 | 1985-10-15 | Kanegafuchi Chemical Ind | Use of pterin derivatives |
GB8318833D0 (en) * | 1983-07-12 | 1983-08-10 | Wellcome Found | Chemical compounds |
JPS5976086A (ja) * | 1982-09-20 | 1984-04-28 | ザ ウエルカム フアウンデ−シヨン リミテツド | プテリジン化合物 |
JPS59112987A (ja) * | 1982-12-20 | 1984-06-29 | Kanegafuchi Chem Ind Co Ltd | 1′,2′―ジアシル―(6r,s)―5,6,7,8―テトラヒドロ―l―ビオプテリンおよびその製法 |
US5196533A (en) * | 1983-04-11 | 1993-03-23 | South Alabama Medical Science Foundation, Usa | Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines |
US4587340A (en) * | 1983-09-19 | 1986-05-06 | Burroughs Wellcome Co. | Biopterin analogs |
JPS60178887A (ja) * | 1984-02-23 | 1985-09-12 | Kanegafuchi Chem Ind Co Ltd | 5,6,7,8−テトラヒドロ−l−ビオプテリンの製造法 |
JPS60199889A (ja) * | 1984-03-24 | 1985-10-09 | Kanegafuchi Chem Ind Co Ltd | 5,6,7,8−テトラヒドロ−l−エリスロ−ビオプテリンの硫酸塩およびその製法 |
US4550109A (en) * | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
CA1262347A (en) * | 1985-01-28 | 1989-10-17 | Suntory Limited | Preparation process of (6r)-tetrahydro-l-biopterin |
ES287056Y (es) * | 1985-05-24 | 1988-06-16 | Salvador Herrero Manuel Ram | Comprobador de condensadores y bobinas de vehiculos automo- viles |
JPS61277618A (ja) * | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
JPS61293983A (ja) * | 1985-06-22 | 1986-12-24 | Kanegafuchi Chem Ind Co Ltd | 5n−アシルテトラヒドロプテリン化合物 |
GB8719367D0 (en) * | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
CA1334654C (en) * | 1987-11-30 | 1995-03-07 | Masayasu Kurono | Intermediates for synthesizing bh _and its derivatives |
US5043339A (en) * | 1988-12-19 | 1991-08-27 | Burroughs Wellcome Co. | Antiviral compounds |
US5198547A (en) * | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
DE4308739C1 (de) * | 1993-03-19 | 1994-06-23 | Henning Berlin Gmbh | Pterinderivate, ihre Herstellung und ihre Verwendung |
DE4418097A1 (de) * | 1994-05-24 | 1995-11-30 | Cassella Ag | Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase |
WO1996003989A1 (fr) * | 1994-08-05 | 1996-02-15 | Suntory Limited | Remede contre la degenerescence spino-cerebelleuse |
DE69733308D1 (de) * | 1996-07-31 | 2005-06-23 | Cmic Co | Aktivsauerstoffaufnehmer enthaltende pterinderivate |
JP4306825B2 (ja) * | 1998-02-27 | 2009-08-05 | アスビオファーマ株式会社 | インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤 |
DE19944767A1 (de) * | 1999-09-17 | 2001-03-29 | Vasopharm Biotech Gmbh & Co Kg | N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US20030078231A1 (en) * | 2001-06-22 | 2003-04-24 | Wilburn Michael D. | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties |
DE10260263A1 (de) * | 2002-12-20 | 2004-07-15 | Biocrates Life Sciences Gmbh | Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen |
US20050137141A1 (en) * | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
US20070167353A1 (en) * | 2003-10-24 | 2007-07-19 | John Hilfinger | Prodrug composition |
AU2004291149C1 (en) * | 2003-11-17 | 2021-01-21 | Biomarin Pharmaceutical Inc. | Methods and Compositions for the Treatment of Metabolic Disorders |
AU2004290692A1 (en) * | 2003-11-17 | 2005-06-02 | Biomarin Pharmaceutical Inc. | Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin |
US7067659B2 (en) * | 2004-04-23 | 2006-06-27 | Duke University | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof |
US8003126B2 (en) * | 2004-11-17 | 2011-08-23 | Biomarin Pharmaceutical Inc. | Stable tablet formulation |
US20060194800A1 (en) * | 2005-01-07 | 2006-08-31 | University Of Strathclyde | Pteridine derivatives as nitric oxide synthase activators |
US20060194808A1 (en) * | 2005-01-14 | 2006-08-31 | Chronorx Llc, An Alaska Limited Liability Company | Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate |
CN101969953B (zh) * | 2008-01-03 | 2013-01-09 | 生物马林药物股份有限公司 | 用于治疗bh4反应性疾病的喋呤类似物 |
-
2008
- 2008-01-09 EP EP08705803A patent/EP2114944A2/en not_active Withdrawn
- 2008-01-09 CA CA002675134A patent/CA2675134A1/en not_active Abandoned
- 2008-01-09 AU AU2008206486A patent/AU2008206486C1/en not_active Ceased
- 2008-01-09 WO PCT/US2008/050637 patent/WO2008089008A2/en active Application Filing
- 2008-01-09 JP JP2009545660A patent/JP2010515747A/ja active Pending
- 2008-01-11 TW TW097101226A patent/TW200843778A/zh unknown
- 2008-01-11 AR ARP080100139A patent/AR064874A1/es unknown
- 2008-01-11 PE PE2008000117A patent/PE20081612A1/es not_active Application Discontinuation
- 2008-01-11 CL CL200800094A patent/CL2008000094A1/es unknown
-
2009
- 2009-07-09 US US12/500,537 patent/US20100016328A1/en not_active Abandoned
-
2011
- 2011-09-16 US US13/235,115 patent/US20120022072A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW200843778A (en) | 2008-11-16 |
WO2008089008A2 (en) | 2008-07-24 |
WO2008089008A3 (en) | 2008-10-09 |
US20100016328A1 (en) | 2010-01-21 |
AU2008206486A1 (en) | 2008-07-24 |
US20120022072A1 (en) | 2012-01-26 |
JP2010515747A (ja) | 2010-05-13 |
AU2008206486C1 (en) | 2013-09-26 |
CA2675134A1 (en) | 2008-07-24 |
CL2008000094A1 (es) | 2008-05-23 |
EP2114944A2 (en) | 2009-11-11 |
AR064874A1 (es) | 2009-04-29 |
AU2008206486B2 (en) | 2013-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20081612A1 (es) | Analogos de las pterinas | |
PE20130279A1 (es) | Compuestos heteroarilo nitrogenados | |
ES2721018T3 (es) | N-Acil-(3-sustituido)-(8-metil)-5,6-dihidro-[1,2,4]triazolo[4,3-a]pirazinas como antagonistas selectivos del receptor NK-3, composición farmacéutica, métodos para su uso en trastornos mediados por el receptor de NK-3 | |
PE20130576A1 (es) | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10 | |
PE20141205A1 (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2 | |
PE20181802A1 (es) | Derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridin-3-il)-6-oxo-6,7-dihidro-5h-pirrolo[2,3-d]pirimidina y los respectivos (1h-indazol-3-il) derivados como moduladores cgmp para el tratamiento de enfermedades cardiovasculares | |
PE20080520A1 (es) | Derivados de benzofuro- y benzotienopirimidina como moduladores del receptor de histamina h4 | |
PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
PE20130012A1 (es) | Derivados de pirazol como inhibidores de jak | |
PE20170144A1 (es) | 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet | |
PE20120031A1 (es) | Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1 | |
PE20141973A1 (es) | Compuestos de heterociclilo como inhibidores de mek | |
PE20091056A1 (es) | PIRIDO[3,2-e]PIRAZINAS, SU PROCEDIMIENTO DE PREPARACION Y USO COMO INHIBIDORES DE FOSFODIESTERASA 10 | |
PE20121614A1 (es) | Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2 | |
PE20141010A1 (es) | Derivados de piridin-2(1h)-ona utiles como medicamentos para el tratamiento de transtornos mieloproliferativos, rechazo de transplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
CR20140099A (es) | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar | |
MA35903B1 (fr) | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
PE20160026A1 (es) | Compuestos heterociclicos como agentes para control de plagas | |
PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
PE20060312A1 (es) | Derivados de tetrahidronaftiridina como ligandos del receptor h3 de histamina | |
EA201170770A1 (ru) | Органические соединения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |